Piqueras, M.; González-Jiménez, P.; Latorre, A.; Tortosa-Carreres, J.; Mengot, N.; Alonso, R.; Reyes, S.; Amara-Elori, I.; Sanz-Herrero, F.; Menéndez, R.;
et al. Evaluation of suPAR as a Key Prognostic Biomarker in Patients with SARS-CoV-2 Pneumonia. Biomedicines 2025, 13, 896.
https://doi.org/10.3390/biomedicines13040896
AMA Style
Piqueras M, González-Jiménez P, Latorre A, Tortosa-Carreres J, Mengot N, Alonso R, Reyes S, Amara-Elori I, Sanz-Herrero F, Menéndez R,
et al. Evaluation of suPAR as a Key Prognostic Biomarker in Patients with SARS-CoV-2 Pneumonia. Biomedicines. 2025; 13(4):896.
https://doi.org/10.3390/biomedicines13040896
Chicago/Turabian Style
Piqueras, Mónica, Paula González-Jiménez, Ana Latorre, Jordi Tortosa-Carreres, Noé Mengot, Ricardo Alonso, Soledad Reyes, Isabel Amara-Elori, Francisco Sanz-Herrero, Rosario Menéndez,
and et al. 2025. "Evaluation of suPAR as a Key Prognostic Biomarker in Patients with SARS-CoV-2 Pneumonia" Biomedicines 13, no. 4: 896.
https://doi.org/10.3390/biomedicines13040896
APA Style
Piqueras, M., González-Jiménez, P., Latorre, A., Tortosa-Carreres, J., Mengot, N., Alonso, R., Reyes, S., Amara-Elori, I., Sanz-Herrero, F., Menéndez, R., & Méndez, R.
(2025). Evaluation of suPAR as a Key Prognostic Biomarker in Patients with SARS-CoV-2 Pneumonia. Biomedicines, 13(4), 896.
https://doi.org/10.3390/biomedicines13040896
